Specific siRNA Targeting Receptor for Advanced Glycation End Products (RAGE) Decreases Proliferation in Human Breast Cancer Cell Lines

International Journal of Molecular Sciences

AL-Madhagi Radia¹  AL-Madhagi Yaser²  Xiaoqian Ma¹  Juan Zhang¹  Cejun Yang¹  Qiong Dong¹  Pengfei Rong¹  Bin Ye¹  Sheng Liu¹ 

[1] Cell Transplantation and Gene Therapy Institute, Department of Radiology, the Third Xiang Ya Hospital of Central South University, Changsha 410013, China; E-Mails:;Center of Molecular Medicine, the First Xiang Ya Hospital of Central South University, Changsha 410078, China; E-Mail:

关键词: RAGE;    siRNA;    proliferation;    breast cancer;   

DOI  :  10.3390/ijms14047959

来源: mdpi

【 摘 要 】

Receptor for Advanced Glycation End Products (RAGE) is an oncogenic trans-membranous receptor overexpressed in various human cancers. However, the role of RAGE in breast cancer development and proliferation is still unclear. In this study, we demonstrated that RAGE expression levels are correlated to the degree of severity of breast cancer. Furthermore, there is a decrease in the proliferation of all sub-types of breast cancer, MCF-7, SK-Br-3 and MDA-MB-231, as a result of the effect of RAGE siRNA. RAGE siRNA arrested cells in the G1 phase and inhibited DNA synthesis (p < 0.05). Moreover, qRT-PCR and Western Blot results demonstrated that RAGE siRNA decreases the expression of transcriptional factor NF-κB p65 as well as the expression of cell proliferation markers PCNA and cyclinD1. RAGE and RAGE ligands can thus be considered as possible targets for breast cancer management and therapy.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland